Tigecycline for the treatment of Acinetobacter infections: A case series

Annals of Pharmacotherapy

Volumn 42, Issue 9, 2008, Pages 1188-1194

  Gallagher, Jason C ^a,b   Rouse, Heather M ^b,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Acinetobacter infections; Glycylcyclines; Gram negative resistance; Tigecycline

Indexed keywords

AMIKACIN; CILASTATIN PLUS IMIPENEM; COLISTIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD DYSCRASIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG INDICATION; HOSPITALIZATION; HUMAN; LIVER FAILURE; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; VOMITING;

ACINETOBACTER INFECTIONS; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BRONCHITIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS; WOUND INFECTION;

EID: 50249156755     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L171     Document Type: Article

References (20)

1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84.
2. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007;59:1210-5.
3. Pickett MJ, Pedersen MM. Nonfermentative bacilli associated with man. II. Detection and identification. Am J Clin Pathol 1970;54:164-77.
4. Suh B, Shapiro T, Jones R, Satishchandran V, Truant AL. In vitro activity of beta-lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21:111-4.
5. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy 2006;26:1099-110.
6. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007;60:1018-29.
7. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 2008;28:235-49.
8. Schafer JJ, Goff DA, Stevenson KB, Mangino JE. Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 2007;27:980-7.
9. Ayan M, Durmaz R, Aktas E, Durmaz B. Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital. J Hosp Infect 2003;54:39-45.
10. Tankovic J, Legrand P, De Gatines G, Chemineau V, Brun-Buisson C. Duval J. Characterization of a hospital outbreak of imipenem-resistant Acinetobacter baumannii by phenotypic and genotypic typing methods. J Clin Microbiol 1994;32:2677-81.
11. Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425-30.
12. Jimenez-Mejias ME, Pachon J, Becerril B, Palomino-Nicas J, Rodriguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;24:932-5.
13. Gallagher JC, Moyer DF, Ang K. Clinical outcomes of using intravenous colistin for multi-drug resistant Gram-negative pathogens(abstract 152). Presented at: American College of Clinical Pharmacy Annual Meeting St. Louis, MO, October 26-29, 2006.
14. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections [erratum Clin Infect Dis 2006;42:1819. Note: dosage error in text]. Clin Infect Dis 2005;40:1333-41.
15. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008;46:567-70.
16. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 2007;59:128-31.
17. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;59:772-4.
18. Thamlikitkul V, Tiengrim S, Tribuddharat C. Comment on: high tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007;60:177-8.
19. Reid GE, Grim SA, Aldeza CA, Janda WM, Clark NM. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 2007;27:1198-201.
20. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(suppl):S341-53.